Literature DB >> 10155290

Economic aspects of pharmacotherapy for chronic constipation.

A P Passmore1.   

Abstract

Constipation is one of the most common digestive complaints. It is a symptom, not a disease. The subjectivity that this involves means that assessments of clinical epidemiology, socioeconomic costs and pharmacotherapy are difficult, since there is no definition of 'normal' bowel habit. Although constipation can affect all ages, the problem increases with age, and is of particular concern for those who are frail and in long term care. Cultural influences may affect the prevalence in older people. Drug therapy of constipation cannot be considered in isolation, since there are issues in the prevention of constipation and the principles of good management that also apply. Furthermore, some consideration of the pathophysiology and diagnosis is important. This is because a number of remediable causes can be identified, and the diagnostic process involves patient education, which in turn may be effective in reducing costs. It is the complaint of constipation which leads either to self-medication or to consultation with the medical profession. Both of these courses of action have a significant influence on utilisation of laxatives (cathartics), obtained both over-the-counter and by prescription. Although there are a large number of laxative preparations available, therapy has changed little in half a century. Costs may vary considerably, and with such a significant problem there is a need for comparative studies. However, study methodologies are difficult, and a significant placebo response may be found. Education and preventive measures have been shown to reduce laxative use and costs in institutions. Unfortunately, there are few comparative studies of individual laxatives and even fewer cost-effectiveness studies. Those that there are have been based in institutions, and so extrapolation to other situations may be difficult. In general, little attention is given to constipation. It is, however, an area with significant resource implications in which education and preventive measures have been shown to be beneficial. Even so, there is still a need for good comparative studies, particularly where cost effectiveness is concerned.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10155290     DOI: 10.2165/00019053-199507010-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  43 in total

Review 1.  Laxatives: replacing danthron.

Authors: 
Journal:  Drug Ther Bull       Date:  1988-07-11

2.  Physician visits in the United States for constipation: 1958 to 1986.

Authors:  A Sonnenberg; T R Koch
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

3.  Alleviation of constipation in the elderly by dietary fiber supplementation.

Authors:  C Hull; R S Greco; D L Brooks
Journal:  J Am Geriatr Soc       Date:  1980-09       Impact factor: 5.562

4.  Effect of dioctyl sodium sulfosuccinate on colonic fluid and electrolyte movement.

Authors:  M Donowitz; H J Binder
Journal:  Gastroenterology       Date:  1975-10       Impact factor: 22.682

5.  Constipation in the elderly living at home. Definition, prevalence, and relationship to lifestyle and health status.

Authors:  W E Whitehead; D Drinkwater; L J Cheskin; B R Heller; M M Schuster
Journal:  J Am Geriatr Soc       Date:  1989-05       Impact factor: 5.562

6.  Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose.

Authors:  F A Lederle; D L Busch; K M Mattox; M J West; D M Aske
Journal:  Am J Med       Date:  1990-11       Impact factor: 4.965

7.  Demographic and dietary determinants of constipation in the US population.

Authors:  R S Sandler; M C Jordan; B J Shelton
Journal:  Am J Public Health       Date:  1990-02       Impact factor: 9.308

8.  Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination.

Authors:  A P Passmore; K Wilson-Davies; C Stoker; M E Scott
Journal:  BMJ       Date:  1993-09-25

Review 9.  Lactulose in the management of constipation: a current review.

Authors:  T V Kot; N A Pettit-Young
Journal:  Ann Pharmacother       Date:  1992-10       Impact factor: 3.154

Review 10.  Constipation: endemic in the elderly? Gerontopathophysiology, evaluation, and management.

Authors:  S C Castle
Journal:  Med Clin North Am       Date:  1989-11       Impact factor: 5.456

View more
  6 in total

Review 1.  Partnering with gastroenterologists to evaluate patients with chronic constipation.

Authors:  Brian E Lacy; Stephen A Brunton
Journal:  MedGenMed       Date:  2005-04-28

Review 2.  What's the 'best buy' for treatment of constipation? Results of a systematic review of the efficacy and comparative efficacy of laxatives in the elderly.

Authors:  M Petticrew; I Watt; M Brand
Journal:  Br J Gen Pract       Date:  1999-05       Impact factor: 5.386

3.  Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK.

Authors:  Angela H Christie; Pearl Culbert; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  The health-related quality of life and economic burden of constipation.

Authors:  Cheryl Dennison; Manishi Prasad; Andrew Lloyd; Samir K Bhattacharyya; Ravinder Dhawan; Karin Coyne
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Epidemiology of constipation in elderly patients. Drug utilisation and cost-containment strategies.

Authors:  F A Lederle
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

6.  Pharmacoeconomic Impact of Low-Dose Macrogol 3350 plus Electrolytes Compared with Lactulose in the Management of Chronic Idiopathic Constipation among Ambulant Patients in Belgium.

Authors:  Julian F Guest; Susan J Varney
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.